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Summary The effects of different doses of angiotensin 11 (0.02 to 0.5 jlg kg-' min-' on mean arterial blood
pressure, tissue blood flow and tissue vascular resistance were investigated in BD9 rats. Blood flow was
measured using the uptake of 12511 or 4C-labelled iodoantipyrine ('25I- IAP and '4C-IAP). Spatial heterogeneity
of blood flow within tumours, before and after angiotensin II infusion, was also measured using '4C-IAP and
an autoradiographic procedure. Mean arterial blood pressure rose steeply with angiotensin II dose. Blood flow
to skeletal muscle, skin overlying the tumour, contralateral skin, small intestine and kidney tended to decline
in a dose-dependent manner. Blood flow to the tumour was also reduced (to 80% of control values) but there
was no dose response. Blood flow to the heart was slightly increased and blood flow to the brain was
unaffected by angiotensin II. Vascular resistance, in all tissues, was increased by angiotensin II infusion. The
increase in tumour tissue was similar to that found in skeletal muscle and small intestine and is likely to be
caused by a direct vasoconstricting effect of the drug rather than autoregulation of tumour blood flow in the
face of an increase in perfusion pressure. The reduction in overall blood flow at the highest perfusion pressure
was due to a preferential effect of angiotensin II at the tumour periphery. These results show that some
tumours, at least, can respond directly to the effects of vasoactive agents.
Selective manipulation of tumour blood flow using vasoactive
agents is potentially useful for some forms of therapy. In
particular, an increase in tumour blood flow relative to sur-
rounding normal tissue would improve the delivery of anti-
cancer drugs. An increase in flow would also improve oxygen
delivery to tumours, resulting in improved oxygenation and
thus response to radiotherapy, as long as any simultaneous
increase in oxygen consumption did not counteract the effect.
Blood flow through a tissue depends upon the perfusion
pressure and the resistance to flow arising from the viscosity
of blood and the geometry of the blood vessels (blood
flow = arteriovenous pressure difference + vascular resis-
tance). Blood flow to experimental tumours has been found
to respond readily to changes in systemic arterial blood
pressure. For instance, controlled bleeding of rats causes a
progressive decline in tumour blood flow (Vaupel, 1975;
Tozer et al., 1990a). Blood flow to such tumours is also
substantially reduced following high doses of vasodilators
such as hydralazine which dramatically lower systemic blood
pressure (e.g. Horsman et al., 1989). Such studies have led to
the suggestion that tumour vascular resistance is minimally
affected by vasoactive drugs (e.g. Horsman et al., 1989; Trot-
ter & Chaplin, 1991). However, the degree to which tumour
vessels respond to drugs will also be dependent on other
factors such as tumour size, site and the proportion of nor-
mal blood vessels incorporated into the tumour mass. Thus,
one of the aims of the present study was to determine the
reactivity of tumour blood vessels to a particular vasoactive
agent, angiotensin II.
Angiotensin II is an endogenous peptide produced locally
in blood vessels and other tissues by the action of renin and
angiotensin converting enzyme on angiotensin I. It is a
potent arteriolar vasoconstrictor which acts by binding to
specific receptors located on the smooth muscle cells. It is
generally supposed that the poorly differentiated blood
vessels of tumours would be lacking in such structures.
Therefore, the rationale for using angiotensin II is that
vasoconstriction in most normal tissues would increase the
perfusion pressure to the tumour with little or no direct
vasoconstriction of the blood vessels supplying the tumour.
The consequence would be an increase in blood flow to the
tumour. Again, this argument may be too simplistic.
The first reports ofusing angotensin II in oncology were as
an aid to tumour imaging by angiography (Kaplan & Books-
tein, 1972; Ekelund & Lunderqvist, 1974). Later, Jirtle et al.
(1978) found that constant intravenous infusion of high dose
angiotensin 11(1.4 Ag min ') into tumour-bearing rats caused
a 4-fold increase in blood flow to the tumour growing in the
mammary gland relative to that in the normal mammary
gland and skin although the absolute blood flow to the
tumour was decreased from 1.3 ml g-min ' to 0.8 mlg' min-'. Subsequent studies have shown that angiotensin II-
infusion can increase absolute, as well as relative, blood flow
in some tumour systems (Tokuda et al., 1990; Hori et al.,
1991; Tanda et al., 1991; Trotter et al., 1991).
These results have led to the concept, particularly in Japan,
ofusing angiotensin II infusion for improving the delivery of
chemotherapeutic drugs to tumours relative to normal tissues
('hypertension chemotherapy') (Suzuki et al., 1981; Sasaki et
al., 1985; Takematsu et al., 1985; Noguchi et al., 1988;
Anderson et al., 1991; Kobayashi et al., 1990 & 1991). Local
intra-arterial administration of angiotensin II to hepatic
tumours and liver metastases also has potential for improv-
ing regional chemotherapy of these tumours (Sasaki et al.,
1985; Hemingway et al., 1991 and Goldberg et al., 1991).
Results from Jirtle et al. (1978) are the only published data
for angiotensin II which are sufficiently quantitative for cal-
culation of vascular resistance. In the present study absolute
blood flow to tumours and normal tissues was measured in
order to calculate tissue vascular resistance and thus deter-
mine whether angiotensin II has any direct vasoconstricting
effects on the blood vessels supplying the tumour. A dose
response for angiotensin II was also obtained in order to
investigate whether there is an optimum dose at which the
effects of an increase in perfusion pressure outweigh any
vasoconstrictior,
lntra-tumour heterogeneity of blood flow also has impor-
tant implications for therapy. Various studies have noted that
angiotensin II tends to improve blood flow in hypovascular
tumour regions (Hori et al., 1985; Burton et al., 1985).
Trotter et al. (1991) suggested that tumour blood flow was
more homogeneous after angiotensin II infusion. On the
other hand, Suzuki et al. (1991) found, using quantitative
autoradiography, that angiotensin II only caused an increase
in tumour blood flow at the well-perfused periphery of trans-
planted rat gliomas. In the present study, we also used an
autoradiographic approach to investigate intra-tumour
heterogeneity of the rat P22 carcinosarcoma.
In short, the aims of this study were (1) to determine a
dose response for the effects of angiotensin II on tumour and
normal tissue blood flow (2) to investigate the mechanisms of
these effects by measuring perfusion pressure and calculating
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tissue vascular resistance with the aim of determining the
reactivity of the tumour blood vessels to the drug (3) to
investigate changes in spatial heterogeneity of blood flow
within tumours during angiotensin II infusion.
Materials and methods
Tumours
A transplanted rat carcinosarcoma, designated P22, was used
for these experiments. This tumour arose in the treated site
of a male BD9 rat following irradiation of the spinal cord in
the cervial region. Maintenance of the tumour line involves
subcutaneous implantation of 1-2 mm3 tumour pieces. Serial
transplantation in male BD9 rats are performed for approx-
imately ten passages before returning to frozen stock of the
spontaneous or 1st passage tumour. Experiments were per-
formed on 5th to 10th passage tumours growing sub-
cutaneously in the left flank of 10 to 12 week old male BD9
rats. Tumours were used for experimentation when they
reached 1-2 g (all 3 orthogonal diameters 10- 15 mm includ-
ing skin thickness).
Bloodflow
Blood flow was measured using the uptake, over a short
infusion time, of the inert, readily diffusible compound, iodo-
antipyrine (IAP). Sampling of arterial blood over the
infusion time, measurement of tissue levels of iodo-antipyrine
at the end of the infusion time and a knowledge of the
relative solubility of iodo-antipyrine in tissue and blood
allows calculation of the specific blood flow to a tissue F
(Kety, 1960).
Rats bearing tumours were anaesthetised by i.p. injection
of fentanyl citrate (0.315 mg kg-') and fluanisone
(10 mgkg-') ('Hypnorm', Crown Chemical Co. Ltd) and
midazolam (5 mg kg-') ('Hypnovel', Roche). 'Portex'
polyethylene catheters (external diameter 0.96mm; internal
diameter 0.58 mm) containing heparinised 0.9% saline were
implanted into a tail artery and two tail veins. The wounds
were sprayed with Xylocaine (Astra Parmaceuticals Ltd) and
strapped. Catheter lengths were standardised to 300 mm.
Rats were kept warm using a thermostatically controlled
heating blanket throughout the catheterising and subsequent
procedures.
One of the tail vein catheters was fitted with a T-piece
connector allowing two syringes to be connected to it. The
first syringe was held in a constant flow infusion pump and
used to infuse angiotensin II (Sigma) at a rate of 0.2ml
kg-' min-' into the rat's circulation. Aliquots of angiotensin
II, which had been made up to a concentration of 200yg
ml-' and stored at - 20°C, were defrosted on each experi-
mental day and were suitably diluted in 0.9% saline to give
angiotensin II doses of between 0.02 and 0.5pgkg-' min-'.
Control rats were infused with 0.9% saline at the same rate.
The second syringe contained 0.3 ml undiluted 'Euthatal'
(May & Baker) for rapid killing of the rat at the end of the
experiment.
The tail artery catheter was connected to a physiological
pressure transducer (Gould) for measurements of mean
arterial blood pressure throughout the infusion time. The
second tail vein catheter was used to heparinise the rat
(0.2 ml of 1000 units ml-' heparin (CP Pharmaceuticals Ltd))
and subsequently to connect a syringe held in a constant flow
infusion pump set at a delivery rate of 0.6ml min-' for
infusion of 0.37 MBq (10jtCi) '251I-iodoantipyrine (1251I-IAP)
(Institute of Cancer Research, England) or 0.56 MBq
(15ptCi) '4C-iodoantipyrine ('4C-IAP) (Amersham). Stock
251I-IAP or '4C-IAP in ethanol was evaporated to dryness and
redissolved in 0.9% saline for infusion.
Blood flow was measured at 20 minutes after the start of
infusion of angiotensin II or saline. At this time, the degree
ofhypertension in all the angiotensin IT-treated rats had been
stable for at least 10 min. The arterial catheter was discon-
nected from the pressure transducer and was used to collect
free-flowing arterial blood during a 30 s infusion of radio-
active iodo-antipyrine into the rat's circulation via the tail
vein catheter. Blood was collected every second into pre-
weighed vials using a fraction collector. At 30 s the rat was
killed by injection of the Euthatal into the venous circulation
and the tumour and various normal tissues excised.
Blood and tissue samples containing '25I-IAP were weighed
and counted for '25I levels using a Wallac Autogamma well-
counter. Ten pIl from each of the blood samples containing
1C were transferred into liquid scintillation vials using a
positive displacement pipette. The remaining blood in each
vial was weighed. Tumours were cut in halfimmediately after
excision and one half rapidly frozen in isopentane cooled to
- 30°C to - 40°C. These samples were stored at - 70°C for
subsequent measurement of tissue levels of '4C using
autoradiography. The other half, as well as the excised nor-
mal tissues containing `4C, were divided into pieces weighing
less than 0.2g and placed in scintillation vials. One ml
'Soluene' tissue solubiliser (Soluene-350, Packard) was added
to each scintillation vial and these were left at 50°C overnight
to dissolve the tissue. Ten ml scintillant (Hionic-Fluor,
Packard) was added to each scintillation vial and the vials
were counted on a Beckman LS 1801 counter with suitable
quench correction.
Blood flow in mls g-' min-' was calculated, for each tis-
sue, using tissue levels of 1251 or 14C measured by scintillation
counting or autoradiography, arterial levels of 125I or 'IC
measured by scintillation counting and the tissue-blood parti-
tion coefficient for IAP in each tissue (Tozer & Morris,
1990b). Mathematical analysis was based on the sample prin-
ciples as described in Tozer & Morris (1990b). However, (1)
arterial input curves (concentration of IAP in arterial blood
vs time after start of infusion of IAP) were deconvolved to
account for delay and dispersion of blood along the plastic
catheters and (2) concentration of IAP vs time, for tissues,
were obtained by convolution of the arterial input using the
relationships derived by Kety (1960). For each blood flow
determination, convolutions were repeated for 200 possible
blood flow values in order to produce a look-up table for
tissue concentration of IAP vs blood flow. These methods
will be published in detail elsewhere.
Tissue vascular resistance (TVR) was calculated from the
relationship,
TVR = perfusion pressure + blood flow.
Venous pressure was taken to be insignificant compared to
arterial pressure, such that measured mean arterial blood
pressure was taken to be equivalent to perfusion pressure.
Autoradiography
Details of the autoradiographic procedure have been pub-
lished in detail elsewhere (Tozer et al., 1990c). Briefly, 20Itm
thick cryostat sections were cut at 1 mm intervals through
each tumour and picked up onto coverslips. These were
mounted onto cardboard sheets together with methyl meth-
acrylate standards of known '4C activity (calibrated against
20gm thick tumour sections of known '4C activity).
Autoradiograms were produced on autoradiographic film
(Hyperfilm-pmax, Amersham) after exposure of several
weeks. Adjacent frozen sections were picked up onto micro-
scope slides, fixed and stained with haematoxylin and eosin
for histological analysis.
Autoradiograms were analysed using an Applied Imaging
image analysis system and 'WBA' software. Autoradio-
graphic images (at least six per tumour) were captured by
camera as optical density images and transformed pixel by
pixel into blood flow images using the same mathematical
analysis as described above. Blood flow measurements from
viable or necrotic tumour regions were extracted from whole
tumour sections by overlaying images of histology (captured
by camera) onto corresponding blood flow images. Results
were expressed as mean blood flow ± standard deviation for
viable regions in each section. This corresponds to 1,000 to
12,000 pixel samples of blood flow per section. Results forANGIOTENSIN II MODIFICATION OF TUMOUR BLOOD FLOW 983
groups of animals were expressed as means ± 1 standard
error of the mean.
Results
Figure 1 shows the relationship between tumour weight and
blood flow in control, saline-infused rats for tumours from
5th to 10th passage away from the spontaneous tumour.
There was a large variation in tumour blood flow from one
rat to another but no overall change with increasing tumour
weight within the range used for experiments. The mean flow
for the whole group was 0.44 ml g-' min-' (n = 29 including
three rats with unknown tumour weight). Tumours from four
different passages were used in Figure 1. Analysis ofvariance
for these four transplants showed a highly significant varia-
tion in flow between them (P<0.0001). Mean and standard
error blood flow for the separate transplants were
0.47 ± 0.04, 0.71 ± 0.04, 0.33 ± 0.04 and 0.34 ± 0.03 mls g1
min-'. That is, the standard errors are of the order of 10%
of the means. This shows that the overall variation in tumour
flow was mainly due to inter-transplant variation. In order to
avoid bias in the data associated with this inter-transplant
variation, the effects of angiotensin II were always assessed
against controls from the same transplantation where inter-
tumour variation in flow is minimal.
Three out of seven of the normal tissues studied (ileum,
kidney and brain) also showed a significant, but smaller,
variation from one experiment to the next (P = 0.02, 0.03
and 0.002 respectively). Control blood flow to the skin over-
lying the tumour, skin from the contralateral flank, skeletal
muscle and heart showed no such variation. The pattern of
variation in blood flow and vascular resistance between one
experiment and the next was the same for ileum, kidney and
brain but different from that in the tumour. This suggests
that the variation in tumour blood flow was due to variation
in the vascular architecture from one transplant group to
another and not to environmental factors. The reasons for
this variation are unknown.
Mean arterial blood pressure in anaesthetised, saline-
infused rats varied between 80 and 100 mmHg. There was no
relationship between pressure and tumour blood flow
between these values. Figure 2 shows the effect of different
doses of angiotensin II on mean arterial blood pressure
measured at 20min after the start of angiotensin infusion.
The pressure rises steeply with dose and plateaus at
-0.2jigkg-1 min-'. Some lung toxicity was observed in the
rats. The highest angiotensin II dose (0.5fg kg-' min-1)
caused the rats some respiratory distress and, on post-
mortem, the lung tissue appeared oedematous. This was
reflected by an increase in lung weight with angiotensin dose
shown in Figure 3. The straight line fit is highly significant
but none of the individual points is statistically different
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Figure 1 Intra-tumour variation in pre-treatment tumour blood
flow. Each point represents a single tumour from four different
tumour passages.
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Figure 2 Relationship between angiotensin II dose and mean
arterial blood pressure measured in the tail artery at 20 min after
the start of angiotensin infusion. Each point represents mean I
s.e.m. (3-10 rats per point).
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Figure 3 Effect of different doses of angiotensin 11 on rat lung weight. Each point represents mean ± I s.e.m. (3-10 rats per point).
from controls except for the highest dose group (Student's
t-test for unpaired data). This lung damage may be a direct
effect of angiotensin II on the lungs or, more likely, may be
an indirect effect of acute left heart failure. Whatever the
cause, all but one of the experiments were performed with
angiotensin doses below 0.2 pgkg-' min-' to avoid
significant lung damage.
Figures 4 and 5 show the effect of angiotensin II on blood
flow and tissue vascular resistance respectively for tumour
and normal tissues. These results were obtained by administering angiotensin II to different groups of rats at
doses between 0.02yIgkg-' min-' and 0.5 jig kg-' min-' for
20 min. Results are plotted relative to control values in order
to minimise the effects of inter-experiment variation in the
controls.
Straight lines have been fitted to the data using weighted least squares regression. In Figure 4, the decrease in blood
flow with increasing blood pressure is significant at the 5%
level (that is the fitted line fits the data better than a horizon-
tal line through the mean for all points) for contralateral
skin, muscle and kidney. The decreasing blood flow for skin
overlying the tumour and ileum is on the borderline of
significance (P = 0.09 and 0.10 respectively). Blood flow to
the tumour, heart and brain shows no variation with increase
in blood pressure.
Skin, kidney, ileum and skeletal muscle are the tissues
most responsive to angiotensin II. Figure 5 shows that vas-
cular resistance was increased by factors of between 2.5 and
5.0 for these tissues at the highest blood pressure. Such an
increase would account for the large increase in mean arterial
blood pressure shown in Figure 2.
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Figure 4 Relationship between angiotensin II-induced increases
in perfusion pressure and tissue blood flow for the P22 tumour
and various normal tissues. Blood flow is plotted as a fraction of
control flow for each passage group. The line at 1.0 represents no
effect of angiotensin II. Each point represents mean ± 1 s.e.m. for
overall tumour blood flow measured using scintillation counting
(6-16 rats per point).
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Figure 5 Relationship between angiotensin II-induced increases
in perfusion pressure and tissue vascular resistance for the P22
tumour and various normal tissues. Vascular resistance is cal-
culated from perfusion pressure
+ blood flow for individual tis-
sues. Blood flow is the overall flow measured using scintillation
counting. Results are plotted as a fraction of control resistance
for each passage group. The line at 1.0 represents no effect of
angiotensin II. Each point represents mean ± I s.e.m. (6-16 rats
per point).
Values above or below 1.0 in Figure 4 represent an in-
crease or decrease in blood flow respectively, following
administration of angiotensin II. Angiotensin II reduced
tumour blood flow to about 80% of control values. This
reduction was significant using the unpaired student's t-test
(P = 0.01) if all tumours were grouped together. Since blood
flow to the normal tissues tended to decrease with increase in
blood pressure but blood flow to the tumour remained
relatively constant, the differential between flow to tumour
and normal tissue varied over the range of angiotensin doses
used. For instance, blood flow to the skin overlying the
tumour was 0.7 of its control flow at the lowest blood
pressure compared to 0.8 for the tumour but only 0.35
compared to 0.8 for the tumour at the highest perfusion
pressure. Blood flow to the heart showed a slight increase
following angiotensin II (P= 0.01, Student's t-test for
unpaired data) for all doses grouped together. The apparent
increase in the brain was not significant even if all doses were
grouped (P= 0.17). This is not surprising since the tight
junctions of the brain endothelial layer are an effective bar-
rier to angiotensin II.
If vascular resistance remains constant, an increase in
blood flow with increasing perfusion pressure follows from
the relationship
blood flow = perfusion pressure + vascular resistance.
The fact that blood flow does not increase with blood
pressure in any of the tissues studied, and actually decreases
in some, means that vascular resistance must be increasing in
all the tissues, including those in the tumour, heart and brain
where there is no dose response for blood flow to angiotensin
II. Figure 5 shows that this is generally the case. All the
individual points in these graphs, except for the lowest dose
of angiotensin II in the ileum and skeletal muscle, represent a
significant increase in vascular resistance following angioten-
sin II administration (Student's t-test for unpaired data). The
increase in tissue vascular resistance with increase in blood
pressure is significant at the 5% level for contralateral skin
and kidney. It is on the borderline of significance for skin
overlying the tumour, ileum, skeletal muscle and brain
(P = 0.09, 0.11, 0.06 and 0.06 respectively). Although vas-
cular resistance in the tumour and heart tends to increase,
this is not significant for the numbers of animals used
(P = 0.19 and P= 0.21 respectively, Student's t-test for
unpaired data). The increase in vascular resistance must be a
direct response to angiotensin II in some tissues but could be
a secondary response to an increase in blood pressure in
other tissues such as the brain (i.e. autoregulation of blood
flow in the face of an increase in perfusion pressure).
Autoradiograms of tumours were analysed in order to
determine the effect of angiotensin II on the intra-tumour
heterogeneity of blood flow. The coefficient of variation for
all the individual pixel blood flow values within the viable
regions of all the sections from each tumour was used as an
index of heterogeneity. Figure 6 shows the coefficient of
variation for different groups of angiotensin TI-treated rats
relative to those for control rats. Although there is a
tendency for the coefficient of variation to be lower after
angiotensin II administration, none of the values is
significantly different from 1.0 (Student's t-test for unpaired
data). That is, the heterogeneity of blood flow within P22
tumours is neither increased nor decreased significantly fol-
lowing administration of angiotensin II.
Further analysis of the autoradiograms did reveal some
differences between tumours. The necrotic fraction varied
from 0 to 12% of the surface area of individual tumour
sections. Gross necrosis was always accompanied by neglig-
ible flow as previously described for the LBDS, tumour
(Tozer et al., 1990c) and large regions of very low flow were
absent in control tumours which were essentially viable
throughout (six tumours). However, large, well-defined
regions of very low flow were present in three out of 12
angiotensin II-treated tumours which were essentially viable.
Figure 7a illustrates the relationship between blood flow and
necrosis for the tumour with the largest necrotic fraction
studied. Figure 7b illustrates a large, very low flow region
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A comparison of the effect of angiotensin II on blood flow
to different regions within the tumours was also made. Figure
8 shows that angiotensin tended to decrease blood flow more
efficiently in sections cut from the periphery of tumours than
in sections cut from the centre. Peripheral sections from
control tumours tended to have higher flow than central
sections (0.715 ± 0.097 ml gImin' vs 0.425 ± 0.051 ml g'
min-' respectively) although this did not reach statistical
significance (Student's t-test for unpaired data). The differ-
ential effect of angiotensin between peripheral and central
sections only reached statistical significance, for the number
r
1
. of sections analysed, at the highest perfusion pressure. Here, 35 140 145 150 155 160 angiotensin II reduced blood flow in the tumour periphery to
Mean arterial blood pressure (mmHg) 0.6 of the control value (P = 0.02) but not at all in sections
cut from the tumour centre (P = 0.54). Thus the blood flow elatonshpbewee anitni I *idue inreae reduction to 0.8 of the control value in whole tumours
pressure and the coefficient of variation for blood
efficient of variation was calculated from the means (Figure 4), conceals a preferential effect of angiotensin II, at
d deviations of blood flow measured, by autoradiog- this dose, on the tumour periphery.
_____._
raphy, in viable regions of individual 20 gm thick tumour sec-
tions. At least six sections were analysed, per tumour, to obtain a
coefficient of variation for that tumour. Each point represents
mean ± 1 s.e.m. (6-7 rats per point).
Figure 7 a, Blood flow to a P22 tumour following a 20 min infusion of 0.5 gg kg-' min-' angiotensin II. Low blood flow regions
are closely related to necrosis (N). LD represents a viable area of low density cellularity. b, Blood flow to a P22 tumour following
a 20 min infusion of 0.05 fig kg-I min- angiotensin II. The section is essentially viable throughout so that the low blood flow
region is unrelated to necrosis.
0
V
O
0
0
.0
0
O 4" '0- c
0 0
._
C cB O
._
( O
> ._
O CB q0- 0-
r -
._
0)
0
._986 G.M. TOZER & K.M. SHAFFI
= 1.6
0
o 1.4
1.2 entral
0 8 t sections
1.0
0.8
0
0.6 6,peripheral
0
135 140 145 150 155 160
Mean arterial blood pressure (mmHg)
Figure 8 Comparison of the effects of angiotensin II on tumour
blood flow for different tumour regions. Blood flow is plotted as
a fraction of control flow for each group. Each point represents
mean ± 1 s.e.m. for blood flow in individual tumour sections cut
from the periphery or the centre of tumours and analysed using
autoradiography. (6-7 rats per point).
Discussion
The increase in tumour blood flow relative to several normal
tissues, reported here for the rat P22 tumour during
angiotensin II infusion, is consistent with results from other
tumour systems reported in the literature. Our results also
showed that normal kidney, small intestine and skin were
particularly susceptible to the vasoconstricting effects of
angiotensin II. Thus, angiotensin II would be expected to be
useful for chemotherapeutic regimes where these are the
dose-limiting normal tissues. This appears to be the case for
kidney where Kobayashi et al. (1990 and 1991) found a
therapeutic benefit for angiotensin II, in an animal tumour
system, when it was used in combination with DDP (cis-
diamminedichloroplatinum(II)), a drug known to induce
severe nephrotoxicity.
The reduction in absolute blood flow to the P22 tumour
was unexpected but very similar to that reported by Jirtle et
al. (1978) using a microsphere method for measuring
absolute blood flow. Such a reduction could compromise the
tumour micro-environment and thus reduce the efficacy of
certain treatments (e.g. radiotherapy). However, there have
been several reports of an increase in tumour blood flow in
other systems during angiotensin II infusion (Hori et al.,
1991, Tanda et al., 1991, Tokuda et al., 1990). The reasons
for this discrepancy are unclear. The doses of angiotensin II
used in our study tended to be lower than those used in other
studies in order to avoid respiratory distress in our animals.
However, the range of doses we used covered similar levels of
induced hypertension, such that this difference seems an
unlikely reason for the discrepancy. All our results were
obtained at 20 min into the angiotensin II infusion time and
so it is possible that we missed an increase in flow at earlier
times. This also seems unlikely since Jirtle et al. found that
the decrease in blood flow in their system was constant from
1 min after the start of infusion. Different tumours may
respond differently to angiotensin II. Blood flow to the P22
tumour is relatively high and the necrotic fraction is low. We
noted that the batch of tumours with the highest control
blood flow reported here also showed the alrgest response to
angiotensin II. Blood flow to tumours in the Jirtle study was
even higher than for the P22 tumour (1.3 ml g-' min-').
Conversely, the subcutaneous tumours used in the Japanese
studies, which consistently showed an improvement in blood
flow following angiotensin II administration, had rather low
pre-treatment blood flow (around 0.2mlmin-'g-1 for the
AH109A tumour and the LY80 tumour, a Yoshida rat
ascites hepatoma and a subline of the Yoshida sarcoma
respectively) (Hori et al., 1991). This could be related to the
large size (3 cm) of these tumours which could reflect a high
interstitial fluid pressure causing vascular collapse. If this
were the case, then angiotensin II may be effective in increas-
ing blood flow to these tumours, but not to the P22 tumours,
by opening up the previously collapsed vessels. Alternatively,
large tumours would have a low fraction of pre-existing
normal blood vessels which are likely to be more responsive
to the vasoconstrictor effects of angiotensin II than the newly
formed tumour blood vessels.
We have also found that a first passage transplant of the
P22 tumour (control flow 0.68 ± 0.07 ml g-1 min-') showed a
particularly large decrease in flow with angiotensin II
administration (a reduction to 0.5 of control flow, unpub-
lished data). Thus response to angiotensin II may be related
to passage number as well as pre-treatment blood flow.
Generally, the response of tumour blood vessels to a par-
ticular vasoactive agent is likely to be very variable depend-
ing upon their smooth muscle investiture, possession of the
relevant receptors and physiological parameters such as
microvascular blood pressure and interstitial fluid pressure.
The application of blood flow modifiers in the clinic is
limited by the unpredictability of the tumour response. Hirst
et al. (1991) have shown that even the same tumour growing
in different sites in the mouse can respond very differently to
angiotensin II. We are currently investigating whether the
frequency of angiotensin II receptors in frozen tumour sec-
tions are dependent on site, size, passage number and intra-
tumour variations in blood flow with the aim of predicting
tumour blood flow response to this particular vasoactive
agent.
The reduction in blood flow for the P22 tumour is accom-
panied by an increase in vascular resistance which is of the
same order as skeletal muscle and kidney. Assuming that
angiotensin II does not affect viscosity of blood flowing
through the tumour, the increase in vascular resistance
represents significant tumour vasoconstriction. Ex vivo
preparations of perfused P22 tumours have shown no
vasoconstriction in response to an increase in perfusion pres-
sure equivalent to that induced by angiotensin II (Sensky et
al., manuscript submitted for publication). This suggests that
the vasoconstriction is a direct effect of angiotensin II on the
blood vessels supplying the tumour.
Previous authors have suggested that most tumours have
very little capacity for responding directly to vasoactive
agents (e.g. Trotter & Chaplin, 1991; Horsman et al., 1989).
This is certainly not the case for the P22 tumour. It is
important to distinguish between those studies where blood
flow was measured relative to the surrounding normal tissue
and those where absolute blood flow was measured. An in-
crease in the former, which has important implications, in
itself, for delivery of chemotherapeutic agents to tumours,
does not imply an increase in the latter. We found that
angiotensin II increased tumour blood flow relative to
various normal tissues but significantly decreased absolute
flow. Other studies, in different tumour systems, have also
shown a direct response of tumour blood vessels to vasoac-
tive agents (Jirtle et al., 1978, Weiss et al., 1986, Tveit et al.,
1987).
All tested doses of angiotensin II reduced blood flow to the
P22 tumour by a similar amount. These doses covered a
range of perfusion pressures which suggests that angiotensin
II increased tumour vascular resistance in a dose-dependent
manner in order to overcome the tendency for blood flow to
increase with increasing perfusion pressure. The results for
tumour vascular resistance did show a trend towards a dose
response but this was not statistically significant.
Our results for the effect of angiotensin II on blood flow
heterogeneity are not readily comparable with other in the
literature since those studies reported an overall increase, not
decrease, in blood flow in their tumour systems (Hori et al.,
1985; Trotter et al., 1991; Suzuki et al., 1991). In the P22
tumour there was no difference in the overall intra-tumour
heterogeneity of blood flow between control and angiotensin
II-treated rats. This implies that angiotensin II is equally
effective in reducing blood flow in the low flow regions as in
the high flow regions when whole tumours are analysed.
However, the reduction in blood flow at the highest perfusion
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tumour regions. Blood flow to tumour sections cut from the
tumour centre was unchanged. This suggests that there
maybe some vascular collapse in the centre of the P22
tumour which the highest perfusion pressure could overcome.
Vascular collapse may be more pronounced in the tumour
centre than the periphery as a result ofhigher interstitial fluid
pressure (Wiig et al., 1982; Boucher et al., 1990; Less et al.,
1991). Alternatively or, in addition, there may be a higher
density of angiotensin II receptors at the periphery of these
tumours than at the centre, possibly associated with a higher
fraction of normal, incorporated vessels at the periphery than
at the centre. The fact that large regions of very low flow,
unconnected with necrosis, were observed in tumours from a
minority of the angiotensin II-treated rats also suggests that
there may be heterogeneous distribution of angiotensin II
receptors in these tumours.
In summary,
(1) The P22 tumour was found to be directly responsive
to the vasonconstricting effects of angiotensin II. The
response was of the same order as that in skeletal muscle
and kidney.
(2) The vasoconstriction outweighed the effect of an in-
crease in perfusion pressure, induced by angiotensin II,
resulting in a decrease in tumour blood flow.
(3) Overall, the intra-tumour heterogeneity of blood flow
was not altered by angiotensin II, although, for the
highest perfusion pressure studied, the reduction in overall
tumour blood flow was due entirely to the response of the
tumour periphery. In a minority of treated tumours, large
areas of very low flow were observed. These regions were
not related to necrosis.
(4) These results suggest that tumours other than the
P22 could also respond directly to angiotensin II and
other vasoactive agents. Analysis of inter- and intra-
tumour heterogeneity of angiotensin II receptor number,
determination of the ratio of normal to new blood vessels
within tumours and measurement of physiological tumour
parameters such as microvascular pressure and interstitial
fluid pressure is a rational approach to finding a method
for predicting tumour blood flow response.
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funded by the Cancer Research Campaign.
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